AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Myriad Genetics, Inc.
Video analysis: MYGN
All videosNo video analysis for this stock yet. Request one from our team.
News: MYGN
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad's website at investor.myriad.com.
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2026, Myriad Genetics reported that its second-quarter revenue declined 11% year-.
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
Dimensional Fund Advisors LP trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 42.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 739,051 shares of the company's stock after selling 548,396 shares during the quarter. Dimensional
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN
Assenagon Asset Management S.A. decreased its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) by 28.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,031,464 shares of the company's stock after selling 415,497 shares during the quarter. Assenagon Asset Management S.A. owned
Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN)
Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership. Earnings and Valuation This table compares Dyadic
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics (MYGN) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Aug. 10, 2026
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.
